Contact this trialFirst, we need to learn more about you.
PARP Inhibitor
ZEN003694 + Talazoparib for Triple Negative Breast Cancer
Recruiting1 awardPhase 2
Gilbert, Arizona
This trial is testing a new drug combination (ZEN003694 and Talazoparib) in patients with a difficult-to-treat type of breast cancer. The goal is to see if these drugs can work together to stop cancer growth and make it harder for cancer cells to repair themselves.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service